Treatment of thyroid eye disease with satralizumab

JP2026516421APending Publication Date: 2026-05-25CHUGAI PHARMA CO LTD +2
View PDF 3 Cites 0 Cited by

Patent Information

Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
CHUGAI PHARMA CO LTD
Filing Date
2024-04-26
Publication Date
2026-05-25

Smart Images

  • Figure 2026516421000001_ABST
    Figure 2026516421000001_ABST
Patent Text Reader

Abstract

All currently available treatment options for thyroid eye disease (TED) carry substantial potential safety risks. This disclosure provides means for treating or preventing TED, including IL-6 inhibitors such as anti-IL-6 receptor antibodies or their antigen-binding fragments, e.g., satralizumab. TIFF2026516421000013.tif59170
Need to check novelty before this filing date? Find Prior Art